SEC Form 8-K Summary
Registrant: Spring Valley Acquisition Corp., which was pursuing a business combination with NuScale Power, LLC. The report was filed April 20, 2022, under Item 8.01, ahead of the April 28, 2022 special shareholder meeting. The filing does not present quarterly or annual operating results.
Business Context and Transaction Status
- Spring Valley, Merger Sub and NuScale had entered into a merger agreement dated December 13, 2021.
- The Form S-4 registration statement was declared effective April 7, 2022, and a definitive proxy statement was distributed to shareholders of record as of March 25, 2022.
- The special meeting was scheduled for April 28, 2022, to vote on the proposed transactions and related matters.
- The filing supplements the proxy statement in response to two shareholder demand letters alleging material omissions. Spring Valley stated that it believed the claims were without merit and that the supplemental disclosures were made to avoid delay, cost and distraction, without admitting that additional disclosure was legally required.
Financial Metrics and Valuation Information
- The filing provides no actual revenue, net income, cash flow, margin, debt or liquidity figures for Spring Valley or NuScale.
- For valuation purposes, Spring Valley management used estimated 2026 NuScale EBITDA of $434.1 million, assuming margins would normalize in that year.
- The discounted cash flow analysis applied a 14.0x to 16.0x terminal EBITDA multiple and a 27.5% discount rate. The midpoint 15.0x multiple produced a discounted terminal value of approximately $1,932.7 million.
- The resulting estimated enterprise value range for NuScale was $2,085.6 million to $2,343.3 million, with a midpoint of approximately $2,214.5 million, compared with implied transaction enterprise value of $1,886.0 million.
- The comparable companies cited were BWX Technologies, Cameco and Centrus Energy.
Material Changes and Supplemental Disclosures
- The proxy statement was supplemented with an explanation of the expected U.S. federal income tax treatment of redemption rights. A U.S. holder will generally recognize capital gain or loss on redemption, although treatment may differ depending on ownership of NuScale common stock and warrants.
- NuScale contacted approximately 60 SPACs during summer and fall 2021; 14 signed confidentiality agreements, 11 met with management and two conducted site visits.
- The merger agreement provided for NuScale’s officers to continue as officers of the combined company. Board candidates were evaluated from December 2021 through February 2022 based on SEC and NYSE requirements, independence, diversity and relevant experience.
- Following Fluor’s April 4, 2022 sale of preferred units to Japan NuScale Innovation, LLC, that entity received a right to nominate one director, subject to CFIUS approval and acceptance by the combined company’s nominating and governance committee.
- Cowen provided financial analysis, including comparable-company and DCF analyses, without compensation for those services. Cowen and Wells Fargo had deferred IPO underwriting fees, and Cowen and Guggenheim were entitled to customary PIPE placement fees, all conditioned on completion of the transactions.
Outlook, Risks and Unusual Items
- Completion remained subject to shareholder approval, financing, regulatory approvals, satisfaction of closing conditions and other merger agreement requirements.
- Key risks included redemption levels, potential termination rights, delays or failure to close, failure to realize transaction benefits, integration costs, NuScale business rollout and milestone timing, competition, and broader economic, financial, legal and political conditions.
- The 2026 EBITDA estimate and valuation analysis are forward-looking and were expressly described as illustrative rather than guarantees of future performance.
- The filing notes that a required regulatory approval could include CFIUS approval related to the Japan NuScale Innovation transaction and board nomination right.
Investor Verification Checklist
- Verify the shareholder vote and whether the proposed merger ultimately closed.
- Review redemption requests, available trust-account proceeds, PIPE financing and final transaction funding.
- Reconcile the disclosed $1,886.0 million implied transaction enterprise value with the final merger consideration and capitalization.
- Assess the assumptions underlying the $434.1 million 2026 EBITDA forecast, 14.0x–16.0x terminal multiple and 27.5% discount rate.
- Confirm required regulatory approvals, including CFIUS approval, and the final board composition.
- Review the definitive proxy statement, Form S-4 and subsequent filings for updated financial statements, risks, contingencies and closing results.